Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.

Johannes F E MannJohn B BuseThomas IdornLawrence A LeiterRichard E PratleySøren RasmussenTina VilsbøllBenjamin WolthersVlado Perkovic

Published in: Diabetes, obesity & metabolism (2021)

Our results suggest that HbA1c and systolic BP may moderately mediate kidney benefits of liraglutide and semaglutide, with all other variables having a small to no effect. Potential kidney benefits may be driven by other mediators or potentially by direct mechanisms.

Keyphrases

blood pressure
heart failure
left ventricular
risk assessment
climate change
data analysis